Serum-Induced Expression of Brain Natriuretic Peptide Contributes to Its Increase in Patients with HFpEF.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
10 Mar 2022
Historique:
received: 08 02 2022
revised: 06 03 2022
accepted: 08 03 2022
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 9 4 2022
Statut: epublish

Résumé

Brain natriuretic peptide (BNP) levels are increased in both patients with heart failure with preserved (HFpEF) and reduced ejection fraction (HFrEF), but the reasons for this remain unclear. Our purpose was to examine whether serum-induced BNP (iBNP) expression partly contributes to increased BNP in patients with HFpEF. BNP reporter cardiomyocytes from pBNP-luc-KI mice were stimulated with serum from patients with HFpEF or HFrEF (n = 114 and n = 82, respectively). Luciferase activity was examined as iBNP and the iBNP-to-BNP ratio was evaluated. Patient characteristics and clinical parameters were compared, and multivariate regression analysis was performed to determine independent predictors of the iBNP-to-BNP ratio. Female sex and frequencies of atrial fibrillation, hypertension and the use of a calcium channel blocker (CCB) were higher in HFpEF. The iBNP-to-BNP ratio was significantly higher in HFpEF (26.9) than in HFrEF (16.1, p < 0.001). Multivariate regression analysis identified the existence of HFpEF as an independent predictor of the iBNP-to-BNP ratio after adjusting for all other measurements (β = 0.154, p = 0.032). Age, hemoglobin, CCB usage and deceleration time were also independent predictors (β = 0.167, p = 0.025; β = 0.203, p = 0.006; β = 0.138, p = 0.049; and β = 0.143, p = 0.049, respectively). These results indicate that the elevated BNP in patients with HFpEF is partly due to iBNP from the heart.

Identifiants

pubmed: 35328412
pii: ijms23062991
doi: 10.3390/ijms23062991
pmc: PMC8955158
pii:
doi:

Substances chimiques

Biomarkers 0
Natriuretic Peptide, Brain 114471-18-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : the Ministry of Education, Culture, Sports, Science and Technology, Japan
ID : 19K08578

Références

Circ Res. 2014 Jun 20;115(1):97-107
pubmed: 24951760
Circ Res. 2016 Jan 22;118(2):311-29
pubmed: 26838316
JACC Heart Fail. 2014 Apr;2(2):97-112
pubmed: 24720916
Peptides. 2005 Jun;26(6):944-56
pubmed: 15911064
Int J Mol Sci. 2019 Jul 22;20(14):
pubmed: 31336656
Circ Heart Fail. 2013 Mar;6(2):279-86
pubmed: 23271790
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
J Am Coll Cardiol. 2021 Feb 16;77(6):772-810
pubmed: 33446410
FASEB J. 2013 Apr;27(4):1439-49
pubmed: 23271052
Nat Med. 2021 Nov;27(11):1954-1960
pubmed: 34711976
Eur J Heart Fail. 2015 Oct;17(10):1015-21
pubmed: 26198713
Int J Cardiol. 2014 Apr 1;172(3):581-7
pubmed: 24534379
JACC Heart Fail. 2016 Feb;4(2):140-149
pubmed: 26682793
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
PLoS One. 2014 Jun 12;9(6):e99495
pubmed: 24923671
J Am Coll Cardiol. 2012 Jan 31;59(5):442-51
pubmed: 22281246
JACC Heart Fail. 2018 Aug;6(8):701-709
pubmed: 30007554
Eur J Heart Fail. 2015 Apr;17(4):405-15
pubmed: 25739750
PLoS One. 2020 Oct 13;15(10):e0240129
pubmed: 33048975
Eur J Heart Fail. 2019 Oct;21(10):1169-1186
pubmed: 31129923
Circ Heart Fail. 2015 Mar;8(2):286-94
pubmed: 25344549
J Am Coll Cardiol. 2019 Feb 12;73(5):602-611
pubmed: 30732715
J Am Coll Cardiol. 2017 Aug 8;70(6):776-803
pubmed: 28461007
Genesis. 2010 May;48(5):317-27
pubmed: 20162675
Circulation. 2000 Dec 19;102(25):3074-9
pubmed: 11120697
Eur J Heart Fail. 2013 Jun;15(6):604-13
pubmed: 23610137
J Am Coll Cardiol. 2012 Mar 13;59(11):998-1005
pubmed: 22402071
Front Pharmacol. 2021 Nov 24;12:707777
pubmed: 34899286
J Investig Med. 2009 Jan;57(1):29-32
pubmed: 19158604
J Circ Biomark. 2016 Mar 16;5:6
pubmed: 28936254
J Am Soc Echocardiogr. 1992 Nov-Dec;5(6):603-12
pubmed: 1466885
J Cardiol. 2011 Mar;57(2):131-40
pubmed: 21296556
PLoS One. 2015 May 26;10(5):e0124844
pubmed: 26010610
Circ J. 2012;76(7):1662-9
pubmed: 22481105
Am J Med. 1995 Mar;98(3):257-65
pubmed: 7872342
Int J Cardiol. 2014 Aug 20;175(3):395-9
pubmed: 25002320
N Engl J Med. 2002 Jul 18;347(3):161-7
pubmed: 12124404
Lancet. 2003 Jul 26;362(9380):316-22
pubmed: 12892964
Circ J. 2015;79(3):574-82
pubmed: 25746542
JACC Heart Fail. 2017 Jul;5(7):507-517
pubmed: 28624483

Auteurs

Ryuji Okamoto (R)

Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.
Regional Medical Support Center, Mie University Hospital, Tsu 514-8507, Japan.

Ryotaro Hashizume (R)

Department of Pathology and Matrix Biology, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.

Noboru Suzuki (N)

Department of Animal Genomics, Functional Genomics Institute, Mie University Life Science Research Center, Tsu 514-8507, Japan.

Rie Ito (R)

Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.

Tomoko Tokuhara (T)

Laboratory for Animal Resources and Genetic Engineering, RIKEN Center for Biosystems Dynamics Research, Kobe 650-0047, Japan.

Hiroshi Fujiwara (H)

Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.

Ye Zhe (Y)

Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.

Hiromasa Ito (H)

Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.

Takaya Abe (T)

Laboratory for Animal Resources and Genetic Engineering, RIKEN Center for Biosystems Dynamics Research, Kobe 650-0047, Japan.

Kaoru Dohi (K)

Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH